1. Market Research
  2. > Pharmaceutical
  3. > Drug and Medication Market Trends
  4. > Antibacterial Drugs: World Industry and Market Prospects 2015-2025

Antibacterial medicines – your guide to business trends, R&D and future revenues
What’s the future of treatments for human bacterial infections? For those antibiotics you get new revenue predictions, also exploring research and development. Those drugs hold high selling potentials. There you assess results, progress, therapies and opportunities.

Visiongain’s new report forecasts those revenues to 2025 at overall world market, submarket, product and national level. It explains what the future holds. There stay ahead in data on treating microbial diseases, discovering prospects to benefit your work and authority.

Read on to explore those antimicrobial medicines and their sellers, seeing how high that industry’s sales can go.

Forecasts to 2025 and other analyses explain and predict the vast antibacterials market
Why miss business data you need? Why struggle to find it or fall behind? Instead our investigation shows sales results, market shares, multilevel revenue forecasts and commercial trends to help your decisions and influence.

In particular you explore product development, seeing agents shaping the future and assessing their potentials. That study gives 123 tables, 97 charts and three research interviews with authorities.

And the following sections show how that new survey helps your research, analyses and decisions, helping you stay ahead in knowledge.

Sales predictions for the world antibiotics market and submarkets – see what’s possible
What’s that biomedical industry's potential? What’re the secrets of its progress? Discover in our report overall world revenue forecasting to 2025 for those bacteria-treating agents.

Also find individual revenue predictions to 2025 for six therapeutic submarkets at world level:

- Cephalosporins

- Penicillins

- Fluoroquinolones

- Macrolides

- Carbapenems

- Other drug-based therapies for bacterial infections.


There you explore prospects from 2015, discovering potentials of novel agents and generic drugs.

That way find where the money lies. Hear how companies, patients and healthcare providers can benefit, assessing the most important product classes and companies.

That study also predicts and discusses leading antibiotics’ revenue potentials.

Predictions for leading and expected products – what future demand and sales?
How will individual drugs perform to 2025 at world level? Our survey forecasts revenues of 43 agents – original marketed brands, generic compounds and emerging medicines.

You assess top products, including these, seeing what sales they can achieve:

- Zyvox

- Cubicin

- Augmentin

- Zosyn/Tazocin

- Avelox

- Invanz

- Generic amoxcillin

- Tedizolid.


There find medicines and years with highest predicted revenues. You also examine competitors. So discover what’s happening, understanding, challenges, trends and commercial outlooks, including effects of product obsolescence and rising competition.

For that overall market, the new analysis also shows you geographical revenue predictions.

National markets – high needs worldwide for treating infections give rising antibiotic demand
In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2015. See where and how, finding what’s possible.

Our work shows you individual revenue forecasts to 2025 for 12 national markets:

- United States (US)

- Germany, France, UK, Italy and Spain (EU5 countries) and the overall European Union

- China, India, Brazil and Russia (BRIC nations)

- South Korea

- Japan.


For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for treating bacterial infections. There you also assess financial potentials from developing, manufacturing and marketing antibiotics.

And what events change that large, vital medical industry? Our survey shows you, discussing trends, challenges and opportunities.

Market forces and issues – what affects developers, producers and sellers of antibacterials?
That updated report explains issues and events affecting that industry and market from 2015, including these influences:

- Antibacterial drug consumption at national level – demand in developed and developing regions and countries

- Incidence of pneumonia, community acquired urinary tract infections, bacterial skin disorders and upper respiratory tract infections in leading countries

- Generic competition for leading brands – effects of patent expiries and follow on therapies

- Prescription control to combat drug-resistant strains and threats from methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE)

- Drug discovery and development – push and pull incentives, inc. public-private collaborations and other alliances.


And you explore these forces on that industry, among others:

- R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations

- Oxazolidinones and other drug classes to stimulate the market

- Treating and preventing hospital-acquired infections (HAIs)

- Potential for smaller pharma companies to succeed, esp. with partnerships

- Guidelines from regulatory bodies and other healthcare policies – effects of changes.


You discover what the future holds. There explore political, economic, social and technological questions. See, too, how R&D lets companies benefit patients and keeps that industry progressing, including overcoming bacterial resistance and serving emerging needs.

See, then, what’s possible from 2015 for that industry, its technology and participants.

Analysis of top companies and potential for market growth – what revenue possible?
So what happens next? Our study predicts that world market will reach $43.2bn in 2019, with revenue expansion from 2015 to 2025.

In that study discover what drives that commercial expansion. And see what’s possible. In particular you explore activities and potentials of these companies:

- Pfizer

- GlaxoSmithKline

- Novartis

- Merck & Co.

- Cubist Pharmaceuticals

- Bayer.


From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from bacteria-treating drugs. See what the future holds there, finding how you can gain.

Ways Antibacterial Drugs: World Industry and Market Prospects 2015-2025 helps
In particular, visiongain’s investigation gives this information to help your work:

Revenues for antibacterial drugs to 2025 at world level, for 6 submarkets and 43 medicines – assess outlooks for development, production, marketing and sales

Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia – investigate developed and developing countries for potential revenues

Prospects for established competitors, rising companies and new entrants – explore portfolios, technologies, results, strategies, R&D and outlooks for success

Discussions of research and development – see progress in that industry, finding technological, clinical and commercial outlooks and opportunities

Opinions from companies and other organisations – discover, through three interviews, views to help you stay ahead in knowledge

Analysis of what stimulates and restrains that antimicrobial drugs market – assess challenges and strengths, helping you compete and gain advantages.

That report, by our UK-based analysts, gives knowledge to benefit your research, planning, decisions and proposals. There get data leading companies depend on again and again.

Knowledge found nowhere else, helping your work, authority and reputation for insight
Our study gives independent data. There receive competitive intelligence found only in our work, finding where progress, potential and money lie. You explore what the future holds.

With that original research and analysis you’re less likely to fall behind in information or miss opportunity. Through your choice now, find how you could save time and effort. That way, benefit your research, analysis and reputation for insight.

The new report shows potentials of medicines for treating human bacterial diseases. There explore trends and R&D, also discovering sales forecasts. So avoid missing out in technological and commercial knowledge. Please get that study here now.

Table Of Contents

Antibacterial Drugs: World Industry and Market Prospects 2015-2025
Table of Contents
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market, 2015-2025
3.1 Antibacterials' Revenues Plateau between 2009 and 2013
3.2 Antibacterial Agents - Market Segmentation
3.3 Antibiotics Market Forecast, 2015-2025: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2015-2025
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector's Market Shares, 2015-2025
3.7 Pfizer is the Leader in the Antibacterial Drugs Market
3.8 Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast, 2015-2025
4.1 Cephalosporins Market 2013-2014 - No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2015 and 2025
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2015 and 2025
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2015-2025
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) - The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition - Forecast 2015-2025
4.1.7 Sulperazon - India's Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2015-2025
4.1.8 Zinnat/Ceftin - GSK's Established Cephalosporin
4.1.8.1 Continued Decline in Revenue - Forecast 2015-2025
4.1.9 Meiact - A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth - Revenue Forecast 2015-2025
4.1.10 Flomox - Shionogi's Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericisation and Safety to Restrict Sales - Forecast 2015-2025
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2015-2025
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval - Revenue Forecast 2015-2025
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast 2015-2025
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales - Forecast 2015-2025

5. Penicillins Market Forecast, 2015-2025
5.1 Generics and Augmentin Dominate the Penicillins Market in 2013 and 2014
5.2 Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin Drugs, 2015-2025
5.3 Penicillin Antibacterials: Market Forecast 2015-2025
5.4 Drivers and Restraints for the Penicillin Market 2015-2025
5.5 Augmentin - Blockbuster Facing Generic Competition
5.5.1 Augmentin - Challenges in Some Countries
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2015-2025
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2015-2025
5.7 Unasyn - Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues - Forecast 2015-2025
5.8 Amoxil (Amoxicillin) - A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue - Forecast 2015-2025
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2015-2025
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2015-2025

6. Fluoroquinolone Market Forecast, 2015-2025
6.1 The Fluoroquinolone Market 2013-2014
6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2015-2025
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2015-2025
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2015-2025
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2015-2025
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2015-2025
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2010-2013
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2015-2025
6.9 Cirpodex and Cipro - Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2015-2025
6.9.2 Cipro Revenue Forecast 2015-2025: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2015-2025
6.11 Delafloxacin
6.11.1 Revenue Forecast 2015-2025

7. Macrolide Market Forecast, 2015-2025
7.1 Macrolides Market in 2013-2014
7.2 Changing Market Share for Macrolides, 2015-2025
7.3 Macrolide Antibacterials: Market Forecast 2015-2025
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Revenue 2013-2014
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2015-2025
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2015-2025
7.7 Dalacin
7.7.1 Revenue Forecast 2015-2025
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2015-2025
7.9 Solithromycin
7.9.1 Revenue Forecast 2015-2025

8. Carbapenem Market Forecast, 2015-2025
8.1 Carbapenem Market 2013-2014
8.2 Changing Market Share for Carbapenems, 2015-2025
8.3 Carbapenem Market Forecast, 2015-2025
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and ?-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2015-2025
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2015-2025
8.7 Invanz
8.7.1 Revenue Forecast 2015-2025
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2015-2025

9. Other Antibiotic Drugs Forecast, 2015-2025
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2015-2025
9.3 Other Antibacterials: Market Forecast, 2015-2025
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2025
9.5 Zyvox - The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition - When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2015-2025
9.6 Cubicin - The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals - How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2019, Revenue Forecast 2015-2025
9.7 Tygacil - A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2015-2025
9.8 TOBI/TOBI Podhaler - The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2015-2025
9.9 Solodyn - A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2015-2025
9.10 Vibativ - Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US - Revenue Forecast 2015-2025
9.11 Sirturo - A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2015-2025
9.12 Tedizolid - Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2015-2025
9.13 Oritavancin - An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2015-2025
9.14 Dalbavancin - Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2015-2025
9.15 Surotomycin -Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2015-2025
9.16 Nemonoxacin - Taiwan's Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2015-2025

10. The Leading National Markets, 2015-2025
10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2015-2025
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2014
10.4.1 Incidence of Pneumonia in National Markets - Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets - High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets - High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets - Europe Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2014
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending - Market Forecast 2015-2025
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany - Europe's Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2019 to 2025
10.8 Japan - Still the Third Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding - Market Forecast 2015-2025
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth - Market Forecast 2015-2025
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2015-2025
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2015-2025

11. Antibacterials RandD Pipeline Review, 2015
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin - Broad C. difficile Treatment to Reduce Relapse
11.3.2 Tedizolid - More Potent Than Zyvox with Fewer Doses?
11.3.3 Delafloxacin - A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.4 Solithromycin - Fluroketolide with Favourable Side Effect Profile
11.3.5 Eravacycline - Treating Gram-Negative cUTIs and cIAIs
11.3.6 Plazomicin - Straight to PIII in Carbapenem Resistant Infections
11.3.7 Cadazolid: Largest PIII C. Difficile Trial
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Avarofloxacin is Reportedly Still Waiting for a Partner
11.4.3 MK-7655 and Invanz - A Novel ?-Lactamase Combination
11.4.4 Omadacycline - Another Phase III-Ready Partnership
11.4.5 Radezolid - Apparently on Melinta's Back-Burner for Now
11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.7 Sutezolid - Sequella Looking to Combine TB Treatments
11.4.8 Taksta (Fusidic acid) - Cempra's Second Pipeline Candidate
11.4.9 TD-1792 - A Russian Antibacterial Medicine
11.4.10 Brilacidin - A Novel Peptide Antibacterial Agent
11.4.11POL7080 - Polyphor and Roche in Multi-Million Dollar Deal
11.4.12 BC-3781- Unique Mechanism of Action at 23S?
11.5 Inhaled Antibiotics - Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE - Targeting P. aeruginosa
11.5.3 Aeroquin - Better than Podhaler?
11.5.4 BAYQ3939 - Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin - Adjunctive Therapy for VAP
11.6 Biologics - Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A - The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 - Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 - Novel DNA Gyrase Inhibitor
11.7.2 MRX-I - Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 - BTI Class of Antibiotics
11.7.4 Carbavance - to Treat CRE

12. Qualitative Analysis of the Antibacterials Industry and Market, 2015
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance - Nature's Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery - Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT - Building on the GAIN act
12.19.3 EMA Update Guideline - Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development

13. Research Interviews from Our Survey
13.1 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut), and Mr. Pablo Gainza-Cirauqui (Duke University)
13.1.1 OSPREY
13.1.2 OSPREY - Specializes in Accurate Negative Design
13.1.3 Technical Challenges in Predicting Mutations
13.1.4 Success Rate - Top Four Predictions Confirmed in vitro
13.1.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
13.1.6 Further Work: Optimize Antibody for Highest in vivo Efficacy
13.1.7 Anticipate Mutations - Redesign Drugs to Maximize Effective Lifespan
13.2 Professor Dr Helga Rübsamen-Schaeff, AiCuris GmbH and Co. KG
13.2.1 AiCuris GmbH and Co. KG
13.2.2 Antibacterial Market - Driven by Supportive Frameworks and Initiatives
13.2.3 Surveillance Data of CRO in Germany
13.2.4 CPE in Germany - Regional Spread
13.2.5 AIC499 - to Treat Gram-Negative Infections
13.3 Dr Vu Truong, Founder and CSO, Aridis Pharmaceuticals, United States
13.3.1 Opportunities for Antibacterial Monoclonal Antibodies
13.3.2 Positioning Monoclonal Antibacterials in the Clinic
13.3.3 Differentiating Factor for Biological Antibacterials
13.3.4 Hazard Pitfalls in Clinical Development
13.3.5 Trends in Antibacterial Drug Market - Novel Targets Rewarded
13.3.6 The Commercial Hazard of Acute Therapeutics
13.3.7 Progress from Government Incentives, But More to Come on the Manufacturing Side
13.3.8 Bacteriophages, Potentially Innovative Therapeutics

14. Antibacterial Drugs Market to 2025: Conclusions
14.1 Three Blockbuster Antibacterials in 2014, Leading Brands
14.2 The Leading Branded Antibacterial Drugs in 2025
14.3 Signs of Life in the Antibacterial RandD Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development


List of Tables
Table 1.1 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Two Year Growth (%) and CAGR, 2015-2025
Table 2.1 Common Bacterial Infections and Their Causes
Table 2.2 Details of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Diseases Deaths Worldwide, 2010
Table 2.4 Mechanisms of Action for Antibacterial Drugs, 2015
Table 3.1 Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2010-2014
Table 3.2 Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2014
Table 3.3 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Two Year Growth (%) and CAGR, 2015-2025
Table 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2014-2025
Table 3.5 Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2013-2014
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
Table 4.2 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2014
Table 4.3 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 4.4 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2025
Table 4.5 Cephalosporin Market Forecast by Product: Revenue ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 4.6 Cephalosporin Market Forecast by Product: Market Share (%), 2014-2025
Table 4.7 Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.8 Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.9 Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.10 Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.11 Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.12 Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
Table 4.13 Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.14 Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.15 Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 4.16 Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.1 Leading Branded Penicillin Drugs: Important Facts
Table 5.2 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2014
Table 5.3 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2019
Table 5.4 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2025
Table 5.5 Penicillin Market Forecast by Product: Revenue ($bn), Biennial Growth (%), CAGR (%), 2015-2025
Table 5.6 Penicillin Market Forecast by Product: Market Share (%), 2014-2025
Table 5.7 Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.8 Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.11 Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.12 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.1 Leading Branded Fluoroquinolone Drugs: Important Facts
Table 6.2 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2014
Table 6.3 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 6.4 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2025
Table 6.5 Fluoroquinolone Market Forecast by Product: Revenue ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 6.6 Fluoroquinolone Market Forecast by Product: Market Share (%), 2014-2025
Table 6.7 Global Patent Expiration Dates for Avelox
Table 6.8 Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.9 Generic Manufacturers of Levofloxacin, 2014
Table 6.10 Cravit Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.12 Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.13 Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.14 Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 6.15 Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 7.1 Leading Branded Macrolides: Important Facts
Table 7.2 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2014
Table 7.3 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 7.4 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2025
Table 7.5 Macrolide Market Forecasts by Product: Revenues ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 7.6 Macrolide Market Forecast by Product: Market Shares (%), 2014-2025
Table 7.7 Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 7.8 Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 7.9 Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 7.10 Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 7.11 Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 8.1 Leading Branded Carbapenems: Important Facts
Table 8.2 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2014
Table 8.3 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 8.4 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2025
Table 8.5 Carbapenem Market Forecasts by Product: Revenues ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 8.6 Carbapenem Market Forecast by Product: Market Share (%), 2014-2025
Table 8.7 Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 8.8 Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 8.9 Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 8.10 Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.1 Other Leading Branded Antibacterials: Important Facts
Table 9.2 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2014
Table 9.3 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2019
Table 9.4 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2025
Table 9.5 Other Agents: Market Forecasts by Product - Revenues ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 9.6 Other Agents: Market Forecast by Product: Market Share (%), 2014-2025
Table 9.7 Oxazolidinones in Mid to Late Stage Clinical Development, 2014
Table 9.8 Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.9 Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.10 Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.11 TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.12 Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.13 Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.14 Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.15 Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.16 Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.17 Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.18 Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 9.19 Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2014
Table 10.2 Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Two Year Growth (%), and CAGR (%), 2014-2025
Table 10.3 Antibacterial Drug Markets: National and Regional Market Shares (%), 2014-2025
Table 10.4 Incidence of Pneumonia in National Markets, 2014
Table 10.5 Incidence of Community Acquired Urinary Tract Infections in National Markets, 2014
Table 10.6 Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2014
Table 10.7 Incidence of Upper Respiratory Tract Infections in National Markets, 2014
Table 10.8 Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2013
Table 10.9 Antibacterial Drug Consumption in the Smaller National Markets: DDD per capita per day and Absolute DDD per year, 2013
Table 10.10 US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.11 EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 10.12 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.13 French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.15 UK Early Stage Antibacterial Drug Developers, 2014
Table 10.16 UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.17 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.18 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.19 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.20 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Two Year Growth (%), CAGR (%), 2015-2025
Table 10.21 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.22 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.23 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 10.24 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 11.1 Small Molecule Antibacterial Drug in Phase III Development, 2014
Table 11.2 Small Molecule Antibacterial Drug in Phase II Development, 2014
Table 11.3 Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical Development, 2014
Table 11.4 Biological Antibacterial Therapeutics in Clinical Development, 2014
Table 12.1 Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2015-2025
Table 12.2 Bacterial Related Funding for BARDA, 2011-2014
Table 14.1 World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2013, 2014, 2019 and 2025

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Phenoxyethanol Preservatives Market for Home and Personal Care, Pharmaceuticals, Dyes & Inks and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Phenoxyethanol Preservatives Market for Home and Personal Care, Pharmaceuticals, Dyes & Inks and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • $ 4 795
  • Industry report
  • April 2015
  • by Transparency Market Research

Phenoxyethanol preservatives are a type of mono alkyl ethers, which are formed when ethylene oxide reacts with 2-Phenol. These are also obtained naturally from green tea. Phenoxyethanol preservatives possess ...

Sodium ceftiofur Chemical Report

Sodium ceftiofur Chemical Report

  • $ 4 609
  • Industry report
  • July 2015
  • by PureData

Sodium ceftiofur Chemical Report This Sodium ceftiofur Chemical World Consumption Reportt provides data on the net consumption of Sodium ceftiofur in each of the countries listed. The substance covered ...

Cefditoren sodium Chemical Report

Cefditoren sodium Chemical Report

  • $ 4 609
  • Industry report
  • July 2015
  • by PureData

Cefditoren sodium Chemical Report This Cefditoren sodium Chemical World Consumption Reportt provides data on the net consumption of Cefditoren sodium in each of the countries listed. The substance covered ...

Levofloxacin Chemical Report

July 2015 $ 4 609

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.